Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

Abraham S. Kanate, Ambuj Kumar, Peter Dreger, Martin Dreyling, Steven Le Gouill, Paolo Corradini, Chris Bredeson, Timothy S. Fenske, Sonali M. Smith, Anna Sureda, Alison Moskowitz, Jonathan W. Friedberg, David J. Inwards, Alex F. Herrera, Mohamed A. Kharfan-Dabaja, Nishitha Reddy, Silvia Montoto, Stephen P. Robinson, Syed A. Abutalib, Christian GisselbrechtJulie Vose, Ajay Gopal, Mazyar Shadman, Miguel Angel Perales, Paul Carpenter, Bipin N. Savani, Mehdi Hamadani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Observations: The RAND-modified Delphi method was used to generate consensus statements where at least 75% vote in favor of a recommendation was considered as consensus. The process included 3 online surveys moderated by an independent methodological expert to ensure anonymity and an in-person meeting. The panel recommended restricting the histologic categories covered in this project to Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. On completion of the voting process, the panel generated 22 consensus statements regarding post auto-HCT maintenance and/or consolidation therapies. The grade A recommendations included endorsement of: (1) brentuximab vedotin (BV) maintenance and/or consolidation in BV-naïve high-risk HL, (2) rituximab maintenance in MCL undergoing auto-HCT after first-line therapy, (3) rituximab maintenance in rituximab-naïve FL, and (4) No post auto-HCT maintenance was recommended in DLBCL. The panel also developed consensus statements for important real-world clinical scenarios, where randomized data are lacking to guide clinical practice. Conclusions and Relevance: In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a rigorous framework for developing consensus recommendations for post auto-HCT maintenance and/or consolidation therapies in lymphoma..

Original languageEnglish (US)
Pages (from-to)715-722
Number of pages8
JournalJAMA Oncology
Volume5
Issue number5
DOIs
StatePublished - May 2019

Fingerprint

Autologous Transplantation
Hodgkin Disease
Cell Transplantation
Non-Hodgkin's Lymphoma
Lymphoma
Transplantation
Bone Marrow
Maintenance
Transplants
Research
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Follicular Lymphoma
Politics
Secondary Prevention
Recurrence
Pharmaceutical Preparations
Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation : A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. / Kanate, Abraham S.; Kumar, Ambuj; Dreger, Peter; Dreyling, Martin; Le Gouill, Steven; Corradini, Paolo; Bredeson, Chris; Fenske, Timothy S.; Smith, Sonali M.; Sureda, Anna; Moskowitz, Alison; Friedberg, Jonathan W.; Inwards, David J.; Herrera, Alex F.; Kharfan-Dabaja, Mohamed A.; Reddy, Nishitha; Montoto, Silvia; Robinson, Stephen P.; Abutalib, Syed A.; Gisselbrecht, Christian; Vose, Julie; Gopal, Ajay; Shadman, Mazyar; Perales, Miguel Angel; Carpenter, Paul; Savani, Bipin N.; Hamadani, Mehdi.

In: JAMA Oncology, Vol. 5, No. 5, 05.2019, p. 715-722.

Research output: Contribution to journalArticle

Kanate, AS, Kumar, A, Dreger, P, Dreyling, M, Le Gouill, S, Corradini, P, Bredeson, C, Fenske, TS, Smith, SM, Sureda, A, Moskowitz, A, Friedberg, JW, Inwards, DJ, Herrera, AF, Kharfan-Dabaja, MA, Reddy, N, Montoto, S, Robinson, SP, Abutalib, SA, Gisselbrecht, C, Vose, J, Gopal, A, Shadman, M, Perales, MA, Carpenter, P, Savani, BN & Hamadani, M 2019, 'Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT', JAMA Oncology, vol. 5, no. 5, pp. 715-722. https://doi.org/10.1001/jamaoncol.2018.6278
Kanate, Abraham S. ; Kumar, Ambuj ; Dreger, Peter ; Dreyling, Martin ; Le Gouill, Steven ; Corradini, Paolo ; Bredeson, Chris ; Fenske, Timothy S. ; Smith, Sonali M. ; Sureda, Anna ; Moskowitz, Alison ; Friedberg, Jonathan W. ; Inwards, David J. ; Herrera, Alex F. ; Kharfan-Dabaja, Mohamed A. ; Reddy, Nishitha ; Montoto, Silvia ; Robinson, Stephen P. ; Abutalib, Syed A. ; Gisselbrecht, Christian ; Vose, Julie ; Gopal, Ajay ; Shadman, Mazyar ; Perales, Miguel Angel ; Carpenter, Paul ; Savani, Bipin N. ; Hamadani, Mehdi. / Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation : A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. In: JAMA Oncology. 2019 ; Vol. 5, No. 5. pp. 715-722.
@article{86b225e9d9f54e3daba7d50f1500f3bb,
title = "Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT",
abstract = "Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Observations: The RAND-modified Delphi method was used to generate consensus statements where at least 75{\%} vote in favor of a recommendation was considered as consensus. The process included 3 online surveys moderated by an independent methodological expert to ensure anonymity and an in-person meeting. The panel recommended restricting the histologic categories covered in this project to Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. On completion of the voting process, the panel generated 22 consensus statements regarding post auto-HCT maintenance and/or consolidation therapies. The grade A recommendations included endorsement of: (1) brentuximab vedotin (BV) maintenance and/or consolidation in BV-na{\"i}ve high-risk HL, (2) rituximab maintenance in MCL undergoing auto-HCT after first-line therapy, (3) rituximab maintenance in rituximab-na{\"i}ve FL, and (4) No post auto-HCT maintenance was recommended in DLBCL. The panel also developed consensus statements for important real-world clinical scenarios, where randomized data are lacking to guide clinical practice. Conclusions and Relevance: In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a rigorous framework for developing consensus recommendations for post auto-HCT maintenance and/or consolidation therapies in lymphoma..",
author = "Kanate, {Abraham S.} and Ambuj Kumar and Peter Dreger and Martin Dreyling and {Le Gouill}, Steven and Paolo Corradini and Chris Bredeson and Fenske, {Timothy S.} and Smith, {Sonali M.} and Anna Sureda and Alison Moskowitz and Friedberg, {Jonathan W.} and Inwards, {David J.} and Herrera, {Alex F.} and Kharfan-Dabaja, {Mohamed A.} and Nishitha Reddy and Silvia Montoto and Robinson, {Stephen P.} and Abutalib, {Syed A.} and Christian Gisselbrecht and Julie Vose and Ajay Gopal and Mazyar Shadman and Perales, {Miguel Angel} and Paul Carpenter and Savani, {Bipin N.} and Mehdi Hamadani",
year = "2019",
month = "5",
doi = "10.1001/jamaoncol.2018.6278",
language = "English (US)",
volume = "5",
pages = "715--722",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation

T2 - A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

AU - Kanate, Abraham S.

AU - Kumar, Ambuj

AU - Dreger, Peter

AU - Dreyling, Martin

AU - Le Gouill, Steven

AU - Corradini, Paolo

AU - Bredeson, Chris

AU - Fenske, Timothy S.

AU - Smith, Sonali M.

AU - Sureda, Anna

AU - Moskowitz, Alison

AU - Friedberg, Jonathan W.

AU - Inwards, David J.

AU - Herrera, Alex F.

AU - Kharfan-Dabaja, Mohamed A.

AU - Reddy, Nishitha

AU - Montoto, Silvia

AU - Robinson, Stephen P.

AU - Abutalib, Syed A.

AU - Gisselbrecht, Christian

AU - Vose, Julie

AU - Gopal, Ajay

AU - Shadman, Mazyar

AU - Perales, Miguel Angel

AU - Carpenter, Paul

AU - Savani, Bipin N.

AU - Hamadani, Mehdi

PY - 2019/5

Y1 - 2019/5

N2 - Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Observations: The RAND-modified Delphi method was used to generate consensus statements where at least 75% vote in favor of a recommendation was considered as consensus. The process included 3 online surveys moderated by an independent methodological expert to ensure anonymity and an in-person meeting. The panel recommended restricting the histologic categories covered in this project to Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. On completion of the voting process, the panel generated 22 consensus statements regarding post auto-HCT maintenance and/or consolidation therapies. The grade A recommendations included endorsement of: (1) brentuximab vedotin (BV) maintenance and/or consolidation in BV-naïve high-risk HL, (2) rituximab maintenance in MCL undergoing auto-HCT after first-line therapy, (3) rituximab maintenance in rituximab-naïve FL, and (4) No post auto-HCT maintenance was recommended in DLBCL. The panel also developed consensus statements for important real-world clinical scenarios, where randomized data are lacking to guide clinical practice. Conclusions and Relevance: In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a rigorous framework for developing consensus recommendations for post auto-HCT maintenance and/or consolidation therapies in lymphoma..

AB - Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Observations: The RAND-modified Delphi method was used to generate consensus statements where at least 75% vote in favor of a recommendation was considered as consensus. The process included 3 online surveys moderated by an independent methodological expert to ensure anonymity and an in-person meeting. The panel recommended restricting the histologic categories covered in this project to Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. On completion of the voting process, the panel generated 22 consensus statements regarding post auto-HCT maintenance and/or consolidation therapies. The grade A recommendations included endorsement of: (1) brentuximab vedotin (BV) maintenance and/or consolidation in BV-naïve high-risk HL, (2) rituximab maintenance in MCL undergoing auto-HCT after first-line therapy, (3) rituximab maintenance in rituximab-naïve FL, and (4) No post auto-HCT maintenance was recommended in DLBCL. The panel also developed consensus statements for important real-world clinical scenarios, where randomized data are lacking to guide clinical practice. Conclusions and Relevance: In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a rigorous framework for developing consensus recommendations for post auto-HCT maintenance and/or consolidation therapies in lymphoma..

UR - http://www.scopus.com/inward/record.url?scp=85062339450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062339450&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.6278

DO - 10.1001/jamaoncol.2018.6278

M3 - Article

C2 - 30816957

AN - SCOPUS:85062339450

VL - 5

SP - 715

EP - 722

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 5

ER -